Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35results about How to "Worsening of symptom" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Rapid improvement of cognition in condition related to abeta
InactiveUS20060073149A1Rapid improvement of cognitionRapid of cognitionNervous disorderImmunoglobulins against animals/humansCognition.knowledgeS syndrome
The present invention is a method for effecting rapid improvement in cognition in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises administering anti-Aβ antibodies to the subject, especially antibodies having a high affinity for soluble forms of Aβ. X-15240
Owner:BALES KELLY +2
Portable device for monitoring and reporting of medical information for the evidence -based management of patients with chronic respiratory disease
ActiveUS20130184540A1Improve life expectancyIncreased mortalityTelemedicineDiagnostic recording/measuringDiseaseDisplay device
An integrated tele-health system / device for monitoring and reporting medical information for the evidence-based management of patients with chronic respiratory disease. The device includes a central unit which measures and collects information related to the state of health of the patient, and is provided with elements for wireless or cable transmission of the collected data using a microprocessor based system with a touch screen display, USB communication port and Bluetooth. The device further includes: a removable sensor for the measurement of respiratory air flow and volume, a removable pulse oximetry sensor and a motion sensor. Stored data can be then delivered through landline, broadband, wireless and cell-phone technology to be received by a web server and can then be accessed by medical staff. Being completely portable, the device is provided with a battery of known type, which can be substituted by the user or can be rechargeable.
Owner:M I R SPA
NANO delivery systems
ActiveUS20150037427A1Prevent leakageUndesired symptomPowder deliveryOrganic active ingredientsNanocarriersActive agent
The present invention makes use of a unique methodology of double nano-encapsulation for protecting and controlling the release of active agents, either hydrophobic or hydrophilic, from stable nanoparticles of opposite characteristics. The protection of the active agent was achieved by loading the agent to be protected, into nanocarriers, which were subsequently encapsulated into sub-micron nanoparticles. The sub-micron nanoparticles formation has been successfully achieved by the use of novel nano spray techniques.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Controlled Release Cgrp Delivery Composition for Cardiovascular and Renal Indications
InactiveUS20080069865A1Effect be attenuateLow dosePowder deliveryPeptide/protein ingredientsMaintenance therapyAdvanced stage
The present invention provides methods of treating heart failure and improving renal function, and / or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.
Owner:VASOGENIX PHARMA
Method for selective extraction of cannabinoids from a plant source
ActiveUS20190231833A1High solubilizing powerLow viscosityAntibacterial agentsPowder deliveryBiotechnologyCannabinoid
Provided are methods for selective extraction of cannabinoids, for example cannabidiol (CBD), from a plant source, by using tailored extraction media.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Dilutable formulations of cannabinoids and processes for their preparation
PendingUS20190314326A1Prevent accidental releaseEasy to transformOrganic active ingredientsPowder deliveryCannabinoidMedicinal chemistry
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
InactiveUS20180017577A1Delayed complicationsIncreased riskPeptide/protein ingredientsMammal material medical ingredientsCord blood stem cellCell therapy
Ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and / or tissue. A patient suffering from disease caused in at least some part by ischemia is selected. At least one dose consisting of an effective amount of stem cells is administrated through intravenous (IV), intra thecal, intra-arterial, via catheter into the organ, via Myostar catheter into the heart, intracoronary, intrapericardial, and / or by direct injection into the organ. Effectiveness of the administration is monitored at selected time periods to determine whether there exists an improved clinical indication. A second dose is administered by a method that is at least invasive as that utilized in the prior dose, and the steps are repeated until the clinical indication shows improvement or until there is contraindication to continued treatment. Diseases include at least one of Ischemia, arteriosclerosis, complications of ischemia, decreased perfusion, aging or diabetes.
Owner:FRANCO WAYNE P
Therapeutic agent for rhinitis
InactiveUS20130045921A1Improve breathabilityImprove bitePeptide/protein ingredientsPharmaceutical delivery mechanismC-type natriuretic peptideSide effect
The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects.Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.
Owner:IGISU +1
Method for extraction of an agent from a plant source
ActiveUS20190314432A1Improve extraction efficiencyEasy to useOrganic active ingredientsCosmetic preparationsBiochemical engineeringActive agent
Provided are methods for extraction of various agents, e.g. active agent, from a plant source, specifically with the use of extraction formulations which are based on micellar liquid systems.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Infant sleep sling
Owner:DURHAM UNIV OF
Treatment of Disorders and Diseases of the Colon
InactiveUS20080318931A1Eliminate side effectsUndesired side-effectBiocideDigestive systemTricyclic antidepressantDisease
A method and a composition for the treatment of an Inflammatory Bowel Disease (IBD) or intestine polyposes is described. The method includes the local administration to the colon of a therapeutically effective amount of at least one Selective Serotonin Reuptake Inhibitor (SSRI) or at least one tricyclic antidepressant (TCA).
Owner:RAMOT AT TEL AVIV UNIV LTD +1
Compositions comprising CB receptor agonists, uses thereof and methods for their preparation
ActiveUS9428431B2Higher binding potencyHigh activityBiocideNervous disorderDiseasePharmaceutical drug
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Pt (IV) derivatives and nanocarriers comprising them
ActiveUS10239903B2The drug effect is goodHigh therapeutic effectPlatinum organic compoundsAntineoplastic agentsNanocarriersCancer therapy
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Controlled release CGRP delivery composition for cardiovascular and renal indications
InactiveUS7976847B2Minimizing and attenuating effectReduce dosePowder deliveryPeptide/protein ingredientsMaintenance therapyImproved method
Owner:VASOGENIX PHARMA
Therapeutic agent for rhinitis
ActiveUS20140243271A1Improve breathabilityImprove bitePeptide/protein ingredientsPharmaceutical delivery mechanismC-type natriuretic peptideBULK ACTIVE INGREDIENT
Owner:ENDO YORI +1
Tricyclic compounds, compositions comprising them and uses thereof
ActiveUS9447040B2Delay disease progressionUndesired symptomNervous disorderOrganic chemistryMedicineOverweight
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Chimeric antigen receptors targeting cd79b and cd19
PendingUS20220047636A1Eliminating potential effectSymptoms improvedPolypeptide with localisation/targeting motifImmunoglobulin superfamilyAntigen receptorBinding domain
Described herein are upfront methods for treating a patient suffering from a cancer. The method includes administering to the patient a therapeutically effective amount of an anti-cancer therapy including a chimeric antigen receptor (CAR) including an extracellular domain including a CD79b-binding domain and a CD19-binding domain, wherein the patient has not been previously treated for the cancer. The invention accordingly also relates to methods of producing and utilizing, e.g., T cells including CARs having an extracellular domain that binds CD79b and CD19.
Owner:THE GENERAL HOSPITAL CORP
Fabp4 as a therapeutic target in skin diseases
ActiveUS20200138779A1PPARγ was reducedNegative correlationOrganic active ingredientsAntipyreticInflammatory skin diseaseInflammatory dermatosis
Provided are methods of regulating proliferation and / or differentiation of keratinocytes and immune cells, more specifically to methods of treating pathologies characterized by hyperproliferative keratinocytes or inflammatory skin diseases by administration of FABP4-inhibitor.
Owner:TICURE LTD
Tricyclic compounds, compositions comprising them and uses thereof
ActiveUS20140329877A1Undesired symptomSlow down irreversible damageBiocideNervous disorderOverweightDisease
Tricyclic compounds, compositions and uses thereof in the treatment of at least one disease, disorder or condition such as for example obesity, overweight, abnormal fat-distribution and any conditions or disease associated therewith.
Owner:YISSUM RES DEV CO OF THE HEBREW UNIV OF JERUSALEM LTD
Controlled release cgrp delivery composition for cardiovascular and renal indications
InactiveUS20110244005A1Lower doseMinimizing and attenuating effectPowder deliveryPeptide/protein ingredientsMaintenance therapyImproved method
Owner:VASOGENIX PHARMA
Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
PendingUS20210315908A1Increased riskDoubles riskOrganic active ingredientsPeptide/protein ingredientsCholic acidCholeic Acid
Provided are methods of treating diabetes and / or obesity in a subject in need thereof, and methods of increasing the amount of cholic acid-7-sulfate (CA7S) in a subject. Further provided herein are methods of administering CA7S to a subject. Also provided are compositions and kits comprising cholic acid-7-sulfate, or a salt thereof for use in the treatment of diabetes and / or obesity.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC +1
Pharmaceutical compositions having anti-inflammatory activity
InactiveUS20050277615A1Delay disease progressionUndesired symptomBiocideSugar derivativesAnti-inflammatoryMultiple sklerose
An anti-inflammatory pharmaceutical composition comprising as active ingredient a compound of general formula (I): wherein W represents oxygen or sulfur atoms; R1 represents lower alkyl or lower cycloalkyl; R2 represents halogen, alkenyl, alkynyl or alkylidenhydrazino; R3 represents a lower alkyl, lower cycloalkyl, aryl, (ar)alkyl or anilide, said cycloalkyl, aryl and (ar)alkyl may be substituted with one or more of the groups selected from halogen, hydroxyl, hydroxyalkyl; and a pharmaceutically acceptable additive. The composition may be used to threat diseases such as multiple sclerosis, rheumatoid arthritis and Crohn's disease.
Owner:CAN-FITE BIOPHARMA LTD
Androgen-Receptor (AR) Ligands for Use in the Treatment and Diagnosis of AR-Related Pathologies
InactiveUS20090226368A1Quality improvementAvoid inhibitionBiocideMicrobiological testing/measurementAndrogenPathology diagnosis
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT +1
Method for extraction of an agent from a plant source
ActiveUS11224628B2Improve extraction efficiencyEasy to useCosmetic preparationsOrganic active ingredientsBiochemical engineeringActive agent
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Method for increasing permeability of blood-brain barrier
PendingUS20210290762A1Improve blood-brain barrier permeabilityWorsening of symptomSonopheresisHeavy metal active ingredientsNitric oxideTight junction
The present invention relates to a method for increasing the blood-brain barrier permeability, and more particularly, to a method for increasing the blood-brain barrier permeability, the method including: (S1) a step of delivering a nanogenerator carrying a nitric oxide (NO) donor to a site adjacent to the blood-brain barrier; (S2) a step of delivering a first triggering stimulus to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and (S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.
Owner:POSTECH ACAD IND FOUND
Sulfanylamide derivatives, uses thereof and compositions comprising them
InactiveUS20120264827A1Undesired symptomSlow progression of diseaseBiocideNervous disorderAnticonvulsant AgentEpileptic seizure
The present invention concerns a family of sulfanilamide derivatives of formula (I) as anticonvulsant agents, where R is selected from optionally substituted C4-C9 alkyl, optionally substituted C6-C10 aryl, optionally substituted C6-C10 alkylenearyl and optionally substituted C5-C10heteroaryl; R2 is selected from —H and optionally substituted C1-C6 alkyl; each of R3 and R4, independently of each other, is selected from —H, optionally substituted C1-C6 alkyl, optionally substituted C6-C10 aryl and optionally substituted C5-C10 heteroaryl; n is 0, 1, 2, 3 or 4. The derivatives have been prepared and their anticonvulsant profile was evaluated for the control of epileptic seizures.
Owner:YISSUM RES DEV CO OF THE HEBREW UNIV OF JERUSALEM LTD
Amino-alcohol analogues and uses thereof
InactiveUS20150183721A1Effective amountImprove adverse reactionsBiocideOrganic chemistryDiseaseAlcohol
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Compositions and methods for targeting a viral infection
PendingUS20210338659A1Symptoms improvedDiminishment of extentOrganic active ingredientsOrganic chemistryViral envelopeViral infection
Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.
Owner:CHILDRENS MEDICAL CENT CORP
Nano delivery systems for siRNA
ActiveUS9387180B2Prevent leakageUndesired symptomOrganic active ingredientsVectorsNanocarriersActive agent
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com